Page last updated: 2024-11-05

thalidomide and Cancer of Duodenum

thalidomide has been researched along with Cancer of Duodenum in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Troch, M1
Zielinski, C1
Raderer, M1

Other Studies

1 other study available for thalidomide and Cancer of Duodenum

ArticleYear
Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8

    Topics: Adult; Aged; Conjunctival Neoplasms; Duodenal Neoplasms; Female; Humans; Lymphoma, B-Cell, Marginal

2009